Accepted Manuscript

Research paper

To appear in:

Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors

Laura Schlütke, Markus Immer, Lutz Preu, Frank Totzke, Christoph Schächtele, Michael H.G. Kubbutat, Conrad Kunick

 PII:
 S0939-6411(17)30041-3

 DOI:
 http://dx.doi.org/10.1016/j.ejpb.2017.03.011

 Reference:
 EJPB 12466

European Journal of Pharmaceutics and Biopharmaceutics

Received Date:11 January 2017Revised Date:10 March 2017Accepted Date:13 March 2017



Please cite this article as: L. Schlütke, M. Immer, L. Preu, F. Totzke, C. Schächtele, M.H.G. Kubbutat, C. Kunick, Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors, *European Journal of Pharmaceutics and Biopharmaceutics* (2017), doi: http://dx.doi.org/10.1016/j.ejpb.2017.03.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors

Laura Schlütke,^a Markus Immer,^{a,b} Lutz Preu,^a Frank Totzke,^c Christoph Schächtele,^c Michael H. G. Kubbutat,^c Conrad Kunick^{*a,b}

- ^a Technische Universität Braunschweig, Institut für Medizinische und Pharmazeutische Chemie, Beethovenstraße 55, 38106 Braunschweig, Germany
- ^b Technische Universität Braunschweig, Center of Pharmaceutical Engineering (PVZ), Franz-Liszt-Straße 35A, D-38106 Braunschweig, Germany
- ^c ProQinase GmbH, Breisacher Straße 117, 79106 Freiburg, Germany
- * corresponding author. E-mail address: c.kunick@tu-braunschweig.de

Abstract: Rearrangements of anaplastic lymphoma kinase (ALK) are associated with several cancer diseases. Due to resistance development against existing ALK-inhibitors, new, structurally unrelated inhibitors are required. By a scaffold hopping strategy, 6,8-disubstituted purines were designed as analogues of similar ALK-inhibiting thieno[3,2-*d*]pyrimidines. While the new title compounds indeed inhibited ALK and several ALK mutants in submicromolar concentrations, they retained poor water solubility.

Abbreviations

ALK: anaplastic lymphoma kinase; cMet, hepatocyte growth factor receptor; DIPEA, *N*,*N*-Diisopropylethylamine; DMF, *N*,*N*-Dimethylformamide; EML4, echinoderm microtubule-associated protein-like 4; FDA, Food and Drug Administration; gk, gatekeeper; μW, micro wave; NSCLC, non-small cell lung cancer; pdb, protein data bank; RT: room temperature; TEA, triethly amine; wt, wild type.

1

Download English Version:

https://daneshyari.com/en/article/8411954

Download Persian Version:

https://daneshyari.com/article/8411954

Daneshyari.com